- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Ryan Haumschild Explains How Technology Can Help Practices Juggle Multiple Biosimilars
Technology utilizing electronic medical records pathways can be useful for practices struggling to manage multiple biosimilars for the same reference product, according to Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute.
Technology utilizing electronic medical records pathways can be useful for practices struggling to manage multiple biosimilars for the same reference product, according to Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute.
Transcript
How can technology be used to allow for better biosimilar adoption and adequate oversight, especially in practices that have to carry multiple biosimilars for the same originator?
Haumschild: Yeah, so, technology is always going to be something that's going to help drive the stewardship of biosimilar utilization and biosimilar use as a whole. And I think as we see more agents getting approved, it's very exciting. But once you have your seventh or your eighth biosimilar for a specific indication, how do you control which one you need to order, what are going to be your levels, and what centers are you going to carry them at?
And so, as we design electronic medical record order sets and pathways, we start to specify preferred products. We meet with our payer colleagues to make sure that aligns with their payer approved processes, but at the same time, we start to prefer individual agents. This allows us to streamline the inventory we have on hand, help drive the prescriber to the most appropriate biosimilar use, and lastly, preserve our days cash-on-hand through the use of cash and cash equivalents within our inventory.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
